This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in this journal  Topic Collections  • Statistics and Research Methods  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply

Use of the DMSS database has allowed the largest vaccine safety investigation of optic neuritis ever published; the power to detect an odds ratio of 1.4 for this study's 18-week study interval was high (>0.80). The matched case-control study design is widely regarded as appropriate for investigations of rare diseases such as optic neuritis; a case-control design was used by researchers in another large vaccine safety investigation of optic neuritis.¹

For each case, 3 controls were randomly selected from a pool of eligible controls in the DMSS database and matched by sex, deployment, and military component. Eligible controls were required to have DMSS diagnostic records indicating no history of optic neuropathy, to have served in the US military on the same date of diagnosis as their matched case, and to have had at least 18 weeks of DMSS surveillance data preceding this index date to fully observe their . . . [Full Text of this Article]

AUTHOR INFORMATION

Daniel C. Payne, PhD, MSPH; Charles E. Rose, Jr, PhD; John Kerrison, MD; Aaron Aranas, MBA, MPH; Susan Duderstadt, MD, MPH; Michael M. McNeil, MD, MPH

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Data vs Conclusions in the Optic Neuritis Vaccination Investigation
Meryl Nass
Arch Neurol. 2006;63(12):1809-1810.
EXTRACT | FULL TEXT